Federal medical cannabis registrations are underway, but new supply-chain requirements could affect customers, suppliers, and financial relationships across the industry.
November 3, 2026 | Safe Harbor Financial
For years, cannabis operators have relied on state licenses to determine who they can buy from and sell to. That could change for businesses participating in the new federal medical cannabis framework. On October 30, the Department of Justice announced the first federal registrations covering more than 900 medical cannabis dispensaries across seven states. Alongside that announcement, the Drug Enforcement Administration (DEA) issued guidance addressing which suppliers and customers those businesses can work with.
The central issue is federal eligibility.
Under the DEA's guidance, federally registered medical cannabis businesses and certain applicants awaiting registration generally are expected to conduct covered medical cannabis transactions only with other federally registered businesses or applicants that qualify under the same expedited process. A state cannabis license alone may not satisfy that expectation.
The DEA has told affected applicants to verify their trading partners and establish compliant supply chains by November 29. The guidance is nonbinding, includes limited transitional allowances, and leaves some questions unresolved. Even so, the agency has warned that dealing with ineligible counterparties could put a federal registration or pending application at risk.
Consider a manufacturer that has supplied the same medical dispensaries for years. It may be properly licensed and compliant with state law, yet unable to continue certain transactions if it does not meet the federal eligibility criteria. The consequences could extend beyond registered businesses. Medical and adult-use operators often share suppliers, facilities, and distribution networks. Changes affecting one group can influence inventory, pricing, customer relationships, and cash flow elsewhere in the market.
What the DEA Changed
The initial federal registrations cover qualifying dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia. Additional applications from dispensaries, manufacturers, and distributors remain under review.
Under the federal framework established in April 2026, qualifying medical cannabis activities are subject to Schedule III controls. Adult-use cannabis and activities outside that framework remain under Schedule I. The broader federal rescheduling proceeding remains separate and unresolved. Federal registration is separate from state licensure and carries additional requirements for security, recordkeeping, inventory controls, and other regulated activities.
The October 30 guidance applies to federally registered businesses and certain applicants that submitted complete applications during the April 28 through June 26 expedited window. It addresses which counterparties qualify for covered medical cannabis transactions. The guidance expressly states that it is nonbinding, and questions remain about how it will be interpreted and applied. It includes limited transitional allowances for certain inventory acquired before October 30 and some testing arrangements.
Operators affected by the guidance should work with legal counsel to review customer and supplier eligibility, document their findings, and determine how the federal requirements apply to their operations.
When State Compliance Isn't Enough
Consider a manufacturer supplying 20 licensed dispensaries, with five accounting for 40% of its revenue. If several of those dispensaries receive federal registrations and the manufacturer does not qualify as an eligible supplier, those relationships could be affected. The manufacturer may still be fully compliant with state law. Its products haven't changed. But its ability to serve those customers could depend on federal eligibility requirements that didn't previously apply.
Raw materials may already have been purchased, production scheduled, and packaging ordered. Finished products may be sitting in inventory, while invoices from earlier shipments remain outstanding. The dispensaries may need replacement suppliers, potentially at higher prices or on less favorable payment terms.
Cannabis operators already manage customer and supplier concentration. Federal eligibility introduces another factor. A manufacturer may have a reasonably diversified customer base but find that several major customers are affected by the same federal requirements. A dispensary may purchase from multiple suppliers, only to discover that few qualify for its covered medical transactions.
Distributors add another layer. A cultivator or processor may have limited direct relationships with registered dispensaries but still be exposed if an important distribution partner changes its purchasing practices. For businesses participating in the federal medical framework, it may become necessary to understand the eligibility of customers and suppliers several steps removed from their own operations.
Could Medical and Adult-Use Cannabis Become Two Different Markets?
Medical and adult-use cannabis already operate under different state regulations. But in many markets, they share much of the same commercial infrastructure. Manufacturers serve both types of retailers. Vertically integrated businesses use common facilities, employees, inventory systems, and distribution resources. Suppliers have built their operations around serving as many licensed customers as state law permits.
The federal framework could begin to change those arrangements. Registered medical operators may need to source products through eligible counterparties and maintain the controls required for covered Schedule III activities. Adult-use operators will continue operating under their existing state-regulated systems, subject to the federal restrictions that remain in place. That could lead to differences in supplier availability, pricing, and operating costs.
A registered medical dispensary with a limited pool of eligible suppliers could face higher wholesale prices or less favorable payment terms. An eligible manufacturer might gain access to customers that competitors cannot serve. Manufacturers outside the federal framework could face greater competition for adult-use customers. How much the market changes will depend on additional registrations, the DEA's application of its guidance, and whether existing business structures can accommodate federal requirements.
Federal medical registration may offer advantages, including potentially different federal tax treatment for qualifying activities. It also brings costs for security, inventory controls, recordkeeping, and operational oversight. Vertical integration could help businesses manage supplier dependencies where the relevant entities and activities meet federal requirements, although common ownership alone does not establish eligibility.
Recent DEA actions involving applicants with adult-use operations or affiliations have raised questions about mixed-use businesses. Those questions remain unresolved, and there has been no blanket determination that all businesses in states with both medical and adult-use programs are ineligible. Operators serving both markets should examine how their businesses are structured and where activities overlap. Federal eligibility could increasingly influence which businesses serve which customers, and on what terms.
The Financial Risks Operators Should Watch
Changes to customer and supplier relationships can have financial consequences even when sales remain relatively stable. Three areas deserve attention.
Customer concentration. A manufacturer or cultivator may depend on a handful of customers for a substantial share of revenue. If those customers enter the federal medical framework and existing supplier arrangements become ineligible, the business could lose sales before developing replacement relationships.
Supplier replacement. A dispensary that needs a new supplier may face higher prices, larger minimum orders, or shorter payment terms. Product availability could become an issue, particularly where patients rely on specific products.
Cash conversion. Cannabis businesses often commit cash to cultivation, production, packaging, and distribution well before receiving payment. If a customer relationship changes after those expenses have been incurred, capital can remain tied up in inventory or receivables while payroll, rent, taxes, and other obligations continue.
Consider a dispensary that purchases $100,000 of inventory each month on 30-day payment terms. If a replacement supplier requires payment on delivery, the dispensary could need roughly another $100,000 in working capital during the transition, depending on purchasing and payment timing. Its sales and inventory costs may be unchanged, but its immediate cash requirements have increased. For operators already managing narrow margins and limited access to credit, that can be significant.
Businesses may also face new expenses for compliance systems, security, personnel, legal review, and changes to operating procedures. Potential tax benefits belong in the same financial analysis. Section 280E generally prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses for federal income tax purposes. Qualifying Schedule III medical cannabis activities may receive different treatment.
The tax implications depend on the activities involved, applicable tax periods, and relevant tax rules. Businesses operating in both medical and adult-use markets should be particularly careful about assuming how those benefits will apply. Federal registration does not automatically determine the tax treatment of an entire company. Operators considering the new framework should evaluate the expected benefits against compliance expenses, working capital needs, and potential changes in revenue.
What This Means for Banking and Lending
The new medical registration framework does not automatically change the compliance obligations of financial institutions serving cannabis-related businesses. Banks and credit unions must continue meeting applicable Bank Secrecy Act, anti-money laundering, and other regulatory requirements. They remain responsible for evaluating customers under the laws, guidance, and risk-management policies applicable to their programs. Adult-use operators should not assume their existing banking relationships will change simply because their activities remain outside Schedule III.
For many businesses, the more immediate concern may be how changes in commercial relationships affect their financial position. A manufacturer losing an important customer may need to revise its revenue projections. A dispensary changing suppliers may require additional working capital. A vertically integrated operator separating certain medical and adult-use activities may incur new expenses. These developments can affect cash flow, inventory turnover, collateral, and the ability to service debt.
For lenders, the federal eligibility of major customers and suppliers may become another consideration when evaluating businesses participating in the medical framework. Operators should maintain accurate financial reporting and keep their banking and lending partners informed of material changes in licensing, business activities, ownership, or operating structure, as appropriate.
What Operators Should Do Now
Start with your five largest customers and five largest suppliers. Identify which participate in medical cannabis, which are pursuing federal registration, and which relationships could be affected by the DEA's counterparty guidance. Then examine the financial implications. How much revenue depends on those customers? How quickly could a supplier be replaced? What would happen to inventory, receivables, and cash flow if an important relationship changed?
For businesses with significant exposure, consider the effect of a disruption lasting 30, 60, or 90 days. Those are planning scenarios, not regulatory deadlines. Operators directly participating in the federal medical framework should confirm applicable requirements with qualified legal counsel, review their trading partners, and document their compliance efforts.
The guidance includes limited transitional provisions, so operators should avoid assuming that all existing inventory or supplier arrangements must be discontinued immediately. Adult-use operators may have less immediate work to do, but should understand whether important suppliers or customers could change their operations as a result of federal registration.
Businesses serving both markets should review shared facilities, inventory, distribution, and administrative arrangements with counsel before making structural changes. Operators should distinguish confirmed requirements from assumptions about future federal policy before making costly operational changes.
Where Things Stand
The first federal medical cannabis registrations establish a new pathway for qualifying businesses that have operated under state medical programs for years. Those businesses are part of an industry built around state licensing systems and established commercial relationships. Changing the federal status of one business can affect the customers and suppliers that depend on it.
Some operators may gain new opportunities. Others could face higher costs, narrower purchasing options, or changes to relationships they have relied on for years. For an industry where margins are already under pressure and access to capital remains limited, even temporary disruptions can have lasting financial consequences.
At Safe Harbor Financial, we see how closely cannabis operators' financial health is tied to their customers, suppliers, and operating arrangements. Changes in those relationships can affect cash flow and financing needs well before they show up in reported revenue. Operators should look beyond their own licenses and understand how the new federal framework may affect the businesses they depend on. Those relationships may be where the financial consequences are felt first.
Legal and regulatory disclaimer: This article is provided by Safe Harbor Financial for general informational purposes only, based on publicly available information as of November 3, 2026. It is not legal, tax, accounting, financial, investment, or regulatory advice. Cannabis laws, regulations, agency guidance, and enforcement policies are subject to change and interpretation. Requirements and potential benefits vary by business and jurisdiction. Readers should consult qualified legal, tax, and financial advisers before taking action. Safe Harbor Financial makes no representation or guarantee regarding federal registration, regulatory compliance, tax treatment, banking or lending eligibility, or future regulatory outcomes. Financial services remain subject to applicable laws, institutional policies, and approval requirements.